Two Norwegian oncology companies announced a merger on 30 June that will generate cash for drug development and advance a joint portfolio of radiopharmaceuticals. The companies are BerGenBio ASA and Oncoinvent ASA. The merger follows BerGenBio’s decision to discontinue its lead cancer product, bemcentinib, and join forces with Oncoinvent to continue Norway’s innovation in radiopharmaceuticals.